Journal of ethnopharmacology · 2026
Cardioprotective effects of an ethanol-soluble fraction of Petiveria alliacea L. in hypertensive rats under isoprenaline-induced stress.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pael Luana Ale Bertoncello, Pessoa Luciane Barbosa, da Silva Maria Luiza Fidelis, Marques Aline Aparecida Macedo, Moreno Karyne Garcia Tafarelo, Kittelson Katiana Simões, Silva Bianca Viana, Neto João Pedro Vilella, da Silva Gabriela Pereira, de Moura Costa Caroline, Dos Santos Ariany Carvalho, de Carvalho Telma Lélia Gonçalves Schultz, Machado Camila Dias, da Silva Denise Brentan, Manfron Jane, Junior Arquimedes Gasparotto
Аннотация
ETHNOPHARMACOLOGICAL RELEVANCE: Cardiovascular diseases (CVDs) are the leading cause of hospitalization and death worldwide. The use of complementary therapies, particularly medicinal plants, has become increasingly prevalent as a therapeutic option. Petiveria alliacea L. (Phytolaccaceae) is a prominent species widely distributed across Brazil. Regarding its ethnopharmacological application, studies involving folk healers have documented the use of this species to treat various disorders of the cardiovascular system.
AIM OF THE STUDY: To investigate the cardioprotective effects of an ethanol-soluble fraction obtained from the aerial parts of P. alliacea in hypertensive rats subjected to isoprenaline-induced cardiac stress.
MATERIALS AND METHODS: Aerial parts of P. alliacea were collected, and an aqueous extract was prepared via infusion. This extract was subsequently treated with ethanol to yield the ethanol-soluble fraction of P. alliacea (ESPA). Wistar-Kyoto and spontaneously hypertensive rats (SHR) were assigned to the following experimental groups: naïve, negative control (vehicle), metoprolol (10 mg/kg), and ESPA (30, 100, and 300 mg/kg). All hypertensive groups received isoprenaline (4.5 mg/kg, s.c.) once daily for four consecutive days. After a 28-day treatment period, renal function, electrocardiographic parameters, blood pressure, and mesenteric vascular bed reactivity were assessed. Biochemical markers, histopathology, and cardiac morphometry were also evaluated. Additionally, intracellular cyclic guanosine monophosphate (cGMP) levels were measured in SHR aortic rings.
RESULTS: On the first day, treatment with ESPA (30 mg/kg) induced a significant natriuretic response, increasing urinary Na+ excretion by ∼ 18% compared to the negative control group; after 28 days, animals treated with 100 and 300 mg/kg of ESPA showed a reduction in systolic blood pressure by ∼ 21%, diastolic blood pressure by ∼ 31%, and lipid peroxidation by ∼ 93%, while nitrite levels rose by ∼ 49% compared to negative control animals. Furthermore, treatment with doses of 100 and 300 mg/kg attenuated plasma angiotensin-converting enzyme activity by approximately 38% and aldosterone levels by ∼26%, restoring them to values comparable to the naïve group. Additionally, ESPA (100 and 300 mg/kg) prevented increases in relative heart weight, left ventricular wall thickness, and interventricular septum thickness, specifically reducing left ventricular wall thickness by ∼ 67% compared to the negative control rats. Finally, incubation with ESPA (0.1 and 1 mg/mL) increased intracellular cGMP levels by approximately 42% and 102%, respectively, in SHR rat aortic rings, evidencing an activation of the nitric oxide (NO)/cGMP pathway.
CONCLUSION: Long-term treatment (28 days) with ESPA exerts significant cardioprotective effects in isoprenaline-induced hypertensive rats. This effect appears to be dependent on the activation of the NO/cGMP pathway, coupled with the inhibition of angiotensin-converting enzyme.
AIM OF THE STUDY: To investigate the cardioprotective effects of an ethanol-soluble fraction obtained from the aerial parts of P. alliacea in hypertensive rats subjected to isoprenaline-induced cardiac stress.
MATERIALS AND METHODS: Aerial parts of P. alliacea were collected, and an aqueous extract was prepared via infusion. This extract was subsequently treated with ethanol to yield the ethanol-soluble fraction of P. alliacea (ESPA). Wistar-Kyoto and spontaneously hypertensive rats (SHR) were assigned to the following experimental groups: naïve, negative control (vehicle), metoprolol (10 mg/kg), and ESPA (30, 100, and 300 mg/kg). All hypertensive groups received isoprenaline (4.5 mg/kg, s.c.) once daily for four consecutive days. After a 28-day treatment period, renal function, electrocardiographic parameters, blood pressure, and mesenteric vascular bed reactivity were assessed. Biochemical markers, histopathology, and cardiac morphometry were also evaluated. Additionally, intracellular cyclic guanosine monophosphate (cGMP) levels were measured in SHR aortic rings.
RESULTS: On the first day, treatment with ESPA (30 mg/kg) induced a significant natriuretic response, increasing urinary Na+ excretion by ∼ 18% compared to the negative control group; after 28 days, animals treated with 100 and 300 mg/kg of ESPA showed a reduction in systolic blood pressure by ∼ 21%, diastolic blood pressure by ∼ 31%, and lipid peroxidation by ∼ 93%, while nitrite levels rose by ∼ 49% compared to negative control animals. Furthermore, treatment with doses of 100 and 300 mg/kg attenuated plasma angiotensin-converting enzyme activity by approximately 38% and aldosterone levels by ∼26%, restoring them to values comparable to the naïve group. Additionally, ESPA (100 and 300 mg/kg) prevented increases in relative heart weight, left ventricular wall thickness, and interventricular septum thickness, specifically reducing left ventricular wall thickness by ∼ 67% compared to the negative control rats. Finally, incubation with ESPA (0.1 and 1 mg/mL) increased intracellular cGMP levels by approximately 42% and 102%, respectively, in SHR rat aortic rings, evidencing an activation of the nitric oxide (NO)/cGMP pathway.
CONCLUSION: Long-term treatment (28 days) with ESPA exerts significant cardioprotective effects in isoprenaline-induced hypertensive rats. This effect appears to be dependent on the activation of the NO/cGMP pathway, coupled with the inhibition of angiotensin-converting enzyme.